DMK Pharmaceuticals Corporation (DMKPQ)
DMKPQ Stock Price Chart
Explore DMK Pharmaceuticals Corporation interactive price chart. Choose custom timeframes to analyze DMKPQ price movements and trends.
DMKPQ Company Profile
Discover essential business fundamentals and corporate details for DMK Pharmaceuticals Corporation (DMKPQ) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
14 Aug 1995
Employees
11.00
CEO
Eddie Wabern Glover
Description
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
DMKPQ Financial Timeline
Browse a chronological timeline of DMK Pharmaceuticals Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 28 Jun 2025
Earnings released on 28 Jun 2025
Earnings released on 28 Mar 2025
Earnings released on 26 Dec 2024
Earnings released on 27 Sept 2024
Earnings released on 28 Jun 2024
Earnings released on 25 Jan 2024
Earnings released on 14 Nov 2023
EPS came in at -$0.20 , while revenue for the quarter reached $9.06K .
Earnings released on 30 Jun 2023
EPS came in at -$3.34 , while revenue for the quarter reached $6.95K .
Stock split effective on 22 May 2023
Shares were split 1 : 70 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Mar 2023
EPS came in at -$4.09 , while revenue for the quarter reached $1.45M .
Earnings released on 31 Dec 2022
EPS came in at -$1.55 falling short of the estimated -$1.40 by -10.93%, while revenue for the quarter reached $2.15M , beating expectations by +34.42%.
Earnings released on 29 Sept 2022
EPS came in at -$2.05 surpassing the estimated -$2.10 by +2.24%, while revenue for the quarter reached $1.51M , beating expectations by +201.14%.
Earnings released on 29 Jun 2022
EPS came in at -$3.92 , while revenue for the quarter reached $39.85K .
Earnings released on 30 Mar 2022
EPS came in at -$4.84 falling short of the estimated -$2.45 by -97.74%, while revenue for the quarter reached $1.15M , missing expectations by -37.08%.
Earnings released on 29 Sept 2021
EPS came in at -$5.81 , while revenue for the quarter reached $759.96K .
Earnings released on 29 Jun 2021
EPS came in at -$4.38 , while revenue for the quarter reached $4.01M .
DMKPQ Stock Performance
Access detailed DMKPQ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.